A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C

Background/AimsWhen combined with pegylated interferon alpha-2b (Peg-IFN α-2b) for the treatment of genotype 1 chronic hepatitis C (CHC) in Korea, the current guideline for the initial ribavirin (RBV) dose is based on body weight. However, since the mean body weight is lower for Korean patients than...

Full description

Bibliographic Details
Main Authors: Byung Chul You, Young Seok Kim, Hun il Kim, Se Hun Kim, Seung Sik Park, Yu Ri Seo, Sang Gyune Kim, Se Whan Lee, Hong Soo Kim, Soung Won Jeong, Jae Young Jang, Boo Sung Kim
Format: Article
Language:English
Published: Korean Association for the Study of the Liver 2012-09-01
Series:Clinical and Molecular Hepatology
Subjects:
Ribavirin
Pegylated interferon alpha-2b
Chronic hepatitis C
Sustained virologic response
Koreans
Online Access:http://e-cmh.org/upload/pdf/cmh-18-272.pdf

Internet

http://e-cmh.org/upload/pdf/cmh-18-272.pdf

Similar Items